Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (Nasdaq: SRTS) reported Q1 2026 results: revenue $3.4M versus $8.3M year‑ago, gross margin 29.2%, adjusted EBITDA -$4.2M and net loss $2.6M ($0.16/share). Company shipped 14 SRT systems, expanded Fair Deal placements, launched financing and Sensus Link, and ended the quarter with $18.3M cash and no debt.
Excluding sales to the historically largest customer, revenue rose versus prior‑year comparable quarter, while inventories and prepaid inventory increased.
Sensus Healthcare (NASDAQ:SRTS) will report first quarter 2026 financial results on May 7, 2026 and hold a business update conference call at 4:30 PM Eastern.
The live call will be webcast and available in the company Investor Relations section at www.sensushealthcare.com. Participants may pre-register to receive a unique dial-in or join via the provided toll-free and international numbers.
Summary not available.
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Link, a proprietary cloud-based software and add-on for the SRT-100™ installed base that adds workflow, treatment documentation and operating intelligence.
Sensus Link aims to expand access to advanced operating features, support Fair Deal Agreement and direct-purchase customers, and create a scalable recurring-revenue stream tied to treatment workflows and oversight services. A phased commercial rollout is expected during 2026, subject to commercial terms and customer onboarding.
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Healthcare Financial Services on February 18, 2026 to simplify acquisition of its SRT and IG-SRT systems for dermatology practices with purchase and leasing options.
The program aims to boost conversions, leverage new CPT reimbursement clarity (approximate 300% per-fraction code increase), and lower the breakeven patient threshold to one patient per month, while offering bank-supported leasing subject to customary underwriting.
Sensus Healthcare (Nasdaq: SRTS) reported Q4 2025 revenue of $4.9M and full-year revenue of $27.5M, with a 2025 net loss of $7.7M and Q4 net loss of $3.2M. The company shipped 14 SRT systems in Q4 and 70 for the year, ended 2025 with $22.1M cash and no debt, and recorded 11,411 FDA treatments in 2025.
Critically, new CPT reimbursement codes (effective Jan 1, 2026) increased the SRT delivery rate by ~300% per fraction, which management says provides reimbursement certainty and supports expected sequential revenue growth and full-year profitability in 2026.
Sensus Healthcare (Nasdaq: SRTS) will report fourth quarter and full year 2025 financial results on February 12, 2026. Management will host a conference call at 4:30 p.m. ET to review results, provide a business update and answer questions.
Participants may pre-register to receive dial-in details or join via the provided toll-free numbers and webcast. A telephone replay will be available until March 12, 2026, and an archived webcast will be posted in Investor Relations.
Sensus Healthcare (Nasdaq: SRTS) announced management will meet with healthcare investors January 12–14, 2026 in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. Management highlighted recently established CMS coding validating its superficial radiotherapy for non-melanoma skin cancer, momentum in the Fair Deal Agreement program, and an expanding international footprint. Investors seeking private meetings at the Alliance Advisors IR 22nd Annual Investor Offsite during JPM Week are asked to contact Tirth Patel at tpatel@allianceadvisors.com.
Sensus Healthcare (Nasdaq: SRTS) announced that Larry Biscotti has been appointed to its Board of Directors effective January 7, 2026. The Board now has six directors, including four independent directors.
Mr. Biscotti is president, Imaging for the U.S. and Canada at GE HealthCare and brings 25+ years of executive experience in medical devices, imaging, oncology and radiation therapy. His prior roles include positions at Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine and CTI Molecular Imaging. He holds an MBA from Pepperdine, a BS from Cornell, and completed Harvard Business School’s Program for Leadership Development.
Sensus Healthcare (Nasdaq: SRTS) on November 14, 2025 announced that President Michael Sardano has been named Chief Commercial Officer in a newly created role to lead global sales, marketing and commercial strategy for SRT technologies, Sentinel software and related services.
The expanded role follows a reimbursement milestone from CMS that established CPT codes for SRT and IG-SRT for non-melanoma skin cancer, which the company says has driven increased interest across dermatology and oncology practices. Mr. Sardano will focus on physician adoption, recurring-revenue models and growth in U.S. and international markets.